^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CCW702

    i
    Other names: CCW702
    Associations

    News

    Trials
    Company:
    AbbVie, Scripps Research Institute
    Drug class:
    CD3 agonist, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    CBR-CCW702-3001: First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=22, Terminated, Calibr, a division of Scripps Research | Trial completion date: Dec 2023 --> Oct 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Oct 2022; Business decision
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    CCW702